Streetbeat News

Analyst Ratings

QTWO

Morgan Stanley analyst James Faucette has assumed coverage of Q2 Holdings (QTWO) with an Equal-Weight rating and increased the price target to $50.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:17 pm

ZBH

Needham analyst Mike Matson reiterates a Hold rating on Zimmer Biomet Holdings (NYSE:ZBH), indicating no change in the investment firm's stance on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:17 pm

GPN

Morgan Stanley analyst James Faucette has maintained an Overweight rating on Global Payments (NYSE:GPN) and increased the price target from $160 to $164.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:16 pm

STTK

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Shattuck Labs (NASDAQ:STTK) and maintains a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:15 pm

FRSH

Morgan Stanley analyst Elizabeth Porter maintains an Equal-Weight rating on Freshworks (NASDAQ:FRSH) and lowers the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:15 pm

MA

Morgan Stanley analyst James Faucette has maintained an Overweight rating on Mastercard (NYSE:MA) but lowered the price target from $536 to $524.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:14 pm

ATNM

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Actinium Pharma (AMEX:ATNM) and maintains a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:13 pm

PFE

Morgan Stanley analyst Terence Flynn maintains an Equal-Weight rating on Pfizer (NYSE:PFE) and raises the price target from $28 to $29.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:12 pm

BXC

Craig-Hallum analyst Greg Palm maintains a Buy rating on BlueLinx Holdings (BXC) but lowers the price target from $130 to $125.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:09 pm

BV

BrightView Holdings' shares surged following the announcement of Q2 adjusted EPS results that exceeded expectations. Additionally, Baird reaffirmed a Neutral rating on BrightView but increased its price target from $8.5 to $13.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:09 pm